Alan O'Connell
Partner @ Seroba Life Sciences
Dublin, Ireland
Alan O'Connell is a Series A investor at Seroba Life Sciences in Dublin focused on Biotechnology and Pharmaceutical. Alan O'Connell is based out of Dublin, Dublin and is the Partner of Seroba Life Sciences. Alan previously worked at Elan Corporation as a Joint-Venture Restructuring Team. Alan O'Connell attended the University of London.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 57%
Last updated:
For AI agents: llms.txt
Industries Alan O'Connell invests in
Stages Alan O'Connell invests in
Countries Alan O'Connell invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (57%)
- Pharmaceutical 3 (43%)
- Medical 2 (29%)
- Health Care 2 (29%)
- Biopharma 1 (14%)
Stage
- Series A 3 (43%)
- Series B 3 (43%)
- Seed 1 (14%)
Country
- Canada 1 (14%)
- Ireland 1 (14%)
- Switzerland 1 (14%)
- United States 1 (14%)
- The Netherlands 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Artica Therapeutics specializes in biotechnological research and development for medical devices, pharmaceutical processes, and food. | $12.7M / Seed / Nov 02, 2023 | ||
| Shorla Pharma is an Irish specialty pharmaceutical company. It is growing portfolio brings accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical impact. | $35M / Series B / Oct 04, 2023 | ||
| Shorla Pharma is an Irish specialty pharmaceutical company. It is growing portfolio brings accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical impact. | $8.3M / Series A / Jun 03, 2020 | ||
| Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company located in Hamilton, Ontario, Canada focused on becoming the leader in the targeted alpha therapy field. It is a spinout of the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production centre.Fusion’s deepradiochemistry expertise presents a technology platform that can be replicated to turn internalizing antibodies that have previously demonstrated limited clinical efficacy into highly effective cytotoxic drugs. Fusion’s ability to link the most effective isotopes to the targeting antibody allows for the creation of optimized agents for both diagnostic imaging and radioimmunotherapy (Precision Medicine). Following positive tumor identification with the imaging agent, treatment with the antibody linked to a therapeutic isotope delivers a cytotoxic payload into the cancer cell.Fusion’s lead product candidate, FPX-01, is a precision RIT that is a product of this innovative approach. FPX-01 has been designed to internalize into targeted cancer cells and deliver a lethal and highly localized radioactive payload. The precise targeting of this radiolabeled antibody causes selective and extremely effective cytotoxicity of tumor cells at relatively low doses of radioactivity. | $105M / Series B / Apr 01, 2019 | ||
| Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company located in Hamilton, Ontario, Canada focused on becoming the leader in the targeted alpha therapy field. It is a spinout of the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production centre.Fusion’s deepradiochemistry expertise presents a technology platform that can be replicated to turn internalizing antibodies that have previously demonstrated limited clinical efficacy into highly effective cytotoxic drugs. Fusion’s ability to link the most effective isotopes to the targeting antibody allows for the creation of optimized agents for both diagnostic imaging and radioimmunotherapy (Precision Medicine). Following positive tumor identification with the imaging agent, treatment with the antibody linked to a therapeutic isotope delivers a cytotoxic payload into the cancer cell.Fusion’s lead product candidate, FPX-01, is a precision RIT that is a product of this innovative approach. FPX-01 has been designed to internalize into targeted cancer cells and deliver a lethal and highly localized radioactive payload. The precise targeting of this radiolabeled antibody causes selective and extremely effective cytotoxicity of tumor cells at relatively low doses of radioactivity. | $21M / Series A / Sep 25, 2017 | ||
| Prexton Therapeutics is a Swiss-based biopharmaceutical company, founded in 2012 by Francois Conquet and MS Ventures as part of the Merck Serono Entrepreneur Partnership Program, a facility to support the creation of spin-offs from Merck Serono. Prexton Therapeutics applies a new scientific approach that fully integrates molecular, behavioural andchemistry technologies to address Parkinson’s disease and other brain disorders. Prexton Therapeutics uses its powerful discovery platform to target specific novel compounds focused on the treatment of Parkinson’s disease. | $31.1M / Series B / Feb 07, 2017 | ||
| Heart Metabolics Limited is pioneering a pharmaceutical therapy for the treatment of hypertrophic cardiomyopathy (“HCM”).HCM is a condition in which the heart muscle becomes thick. The thickening makes it harder for blood to leave the heart forcing the heart to work harder to pump blood, leading in many cases to heart failure. Sudden death iscaused frequently.There are over 100,000 cases of HCM in the United States alone, often presenting more severely in young adults and athletes; unfortunately the younger the individual is when diagnosed with HCM, the more likely that the individual has a severe form.Although various cardiovascular drugs are currently used to treat HCM, there are patients who are not being helped by current therapeutics. In response to this medical need and based on encouraging phase II clinical trial results to date, Heart Metabolics is developing perhexiline as a therapeutic for all types of HCM. Perhexiline is currently an approved drug in Australia and New Zealand for the treatment of angina.Heart Metabolics plans to conduct clinical trials in the U.S. and seek FDA approval of perhexiline as an orphan drug; the company currently has such an orphan designation from the FDA. | $20M / Series A / Apr 16, 2014 |
Co-Investors
About Seroba Life Sciences
Seroba is a life sciences venture capital firm, focused on investing in breakthrough healthcare technologies that promise to improve lives and make a difference worldwide. Headquartered in Ireland, the firm works with some of the world’s best entrepreneurs developing innovative medical devices, diagnostics, and therapeutic drugs. It funds new healthcare opportunities through key value-adding stages, assisting its invested companies from inception through development and clinical evaluation, the generation of intellectual property, regulatory approvals and market launch, and partnering with leading pharmaceutical or medtech companies. The Seroba team combines in-depth scientific and medical knowledge with broad regulatory and commercial expertise. They are known for patience, understanding, commitment and passion, well-demonstrated by the caliber of entrepreneurs they back, and an overriding focus on delivering improvements to people's lives and value to their stakeholders.
Seroba Life Sciences Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alan O'Connell
Partner
|
|||
Bruno Montanari
Partner
|
|||
Daniel O' Mahony
Partner
|
|||
Seamus O’Hara
Director
|
|||
Andrew Duignan
CFO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alan O'Connell invest in?
Alan O'Connell invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Alan O'Connell?
Public channels for Alan O'Connell include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Alan O'Connell last invest?
The most recent investment recorded for Alan O'Connell closed in Nov 2023. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
